Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of Health for its Mounjaro (tirzepatide) in KwikPen presentation, marking a significant step in the treatment of weight management and type 2 diabetes. Mounjaro is indicated for adults with obesity (BMI of 30 kg/m^2 or greater) or those who are overweight (BMI of 27 kg/m^2 or greater) with weight-related medical issues such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It is intended to aid in weight loss and maintenance when used with a reduced-calorie diet and increased physical activity. Additionally, Mounjaro serves as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus, as monotherapy or in combination with other treatments.
Mounjaro is the first of its kind in Hong Kong to activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, offering a novel approach to obesity and type 2 diabetes treatment. The approval follows positive results from Phase III studies SURMOUNT and SURPASS, which confirmed the significant efficacy and safety of Mounjaro in blood glucose control and weight loss. Available in six dosages (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and administered via Lilly’s KwikPen, Mounjaro is expected to hit the Hong Kong market by the end of this year.- Flcube.com
